Markets

Insider Trading

Hedge Funds

Retirement

Opinion

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months.

A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.

AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody discovery. Founded in 2012, the company integrates cutting-edge technology, advanced data science techniques, and interdisciplinary expertise to streamline the development of innovative antibody medicines. These medicines target a range of health issues, including cancer, autoimmune disorders, and metabolic conditions, addressing critical therapeutic needs in the biopharmaceutical landscape. AbCellera’s pipeline includes promising candidates such as ABCL635, designed to tackle metabolic and endocrine conditions, and ABCL575, which is focused on treating T-cell-mediated autoimmune conditions like atopic dermatitis. Both programs remain in preclinical stages, with Clinical Trial Applications expected to commence by 2025, a milestone that underscores AbCellera’s commitment to advancing its pipeline with precision and speed.

AbCellera’s success has been bolstered by strategic collaborations with industry giants such as Eli Lilly, Biogen, and AbbVie. These partnerships have enabled the company to leverage partner insights, cutting-edge technologies, and shared expertise to develop highly optimized clinical candidates. Since its inception, AbCellera has initiated an impressive 96 partner programs, with 16 molecules having reached clinical trials, a testament to the effectiveness of its unique platform. The company’s focus extends beyond partnerships, as it has heavily invested in its research infrastructure. By the end of 2025, AbCellera aims to complete its clinical manufacturing facilities, a significant step that will position the company to efficiently bring next-generation antibody therapeutics to market while maintaining high standards of innovation and quality.

In terms of financial performance, AbCellera Biologics Inc. (NASDAQ:ABCL) demonstrated a solid topline of $4.24 million for the first quarter of 2025, bolstered by milestone payments and antibody discovery collaborations. For the full year 2024, the company reported a topline of $28.8 million, further solidifying its financial robustness. With a substantial cash position of $540 million, AbCellera is well-equipped to sustain its growth trajectory. On 15th May, 2025, analysts downgraded their estimates based on revenue estimates being lower than expectations. Overall, however, analysts remain optimistic about the stock, highlighting an average share price projection of $11.43 over the next twelve months, presenting an upside potential of 474.37%.

Overall, AbCellera Biologics Inc. (NASDAQ:ABCL) ranks 7th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!